Investigational drug · Phase 2
SPVN20
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Retinitis Pigmentosa (RP), Rod Cone Dystrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SPVN20"
First trial start
2025
Oct 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPVN20", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinitis Pigmentosa (RP)
- Rod Cone Dystrophy
Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "SPVN20" as an intervention, largest first.
SparingVisionIndustry
NCT07807111 · 27 participants (planned) · Start Oct 8, 2025 · Primary completion Mar 2032
Drug: SPVN20 (high dose); SPVN20 (medium dose) and 1 more · For: Retinitis Pigmentosa (RP); Rod Cone Dystrophy
Sites: Ghent, Belgium; Paris, France; Dublin, Ireland
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Retinitis Pigmentosa (RP)
- NPI-001N-Acetylcysteine AmidePhase 35 trials
Nacuity Pharmaceuticals, Inc. · Retinitis Pigmentosa (RP), Usher Syndrome, Alzheimer´s Disease
- RTx-015Phase 31 trial
Ray Therapeutics, Inc. · Retinitis Pigmentosa (RP), Inherited Retinal Diseases
- Intravitreal of UltevursenPhase 22 trials
Laboratoires Thea · Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind
- OpCT-001Phase 21 trial
BlueRock Therapeutics · Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.